Earnings call transcript: Innate Pharma's Q2 2025 focus on strategic assets
PositiveFinancial Markets

Innate Pharma's recent earnings call highlighted their strategic focus for Q2 2025, showcasing a commitment to advancing key assets in their pipeline. This is significant as it reflects the company's proactive approach to innovation and growth in the competitive biotech landscape, potentially leading to breakthroughs in treatment options.
— Curated by the World Pulse Now AI Editorial System